Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu

Core Insights - Bio-Techne Corp. has launched an expanded menu of RNAscope in situ hybridization probes to enhance spatial biology research and the development of next-generation therapeutics and diagnostics [1][2] - The new RNAscope probe portfolio includes over 70,000 unique probes across more than 450 species, aimed at providing spatial precision with advanced sensitivity and specificity [1][5] Company Developments - The latest development is expected to significantly enhance Bio-Techne's Diagnostics and Spatial Biology segment [2] - Since the announcement on February 20, Bio-Techne shares have dipped by 0.9%, closing at $64.92, but the company is focused on advancing translational research and precision medicine [3] - Bio-Techne has a market capitalization of$10.26 billion and an earnings yield of 2.9%, which is favorable compared to the industry's -30.1% yield [4] Product and Technology Insights - RNAscope technology is the most referenced in the spatial biology industry, providing a single-cell view of disease pathology and therapeutic response [5] - The expanded RNAscope probe portfolio is designed to accelerate the validation of new RNA biomarkers from single-cell genomics and spatial discovery programs [5][6] - The probes are available for purchase on Bio-Techne's website and can be used with R&D Systems antibodies to illuminate changes in cell phenotypes [6] Industry Prospects - The global spatial genomics and transcriptomics market was valued at $232.5 million in 2022 and is projected to grow at a compound annual growth rate of 12.2% through 2030 [8] - Demand for spatial genomics and transcriptomics is increasing, particularly in drug discovery and development for neurodegenerative disorders and cancer [10] Recent Updates - Bio-Techne has also released the GMP Transposase mRNA for the TcBuster non-viral genome engineering system, supporting the development of immune cell and stem cell-based therapies [11]